Trial · NCT07900178
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weight change | Assessed at follow-up (at least 12 months after programme completion). | Change in weight from the final programme measurement (measured between 21 and 24 months) to follow-up-assessment |
| Primary | Proteomics and metabolomics related to weight-loss and weight-gain. | Assessed at follow-up (at least 12 months after programme completion). | |
| Primary | Change in skeletal muscle mass | Assessed at follow-up (at least 12 months). | We will calculate mean changes in skeletal muscle mass measured by bioimpedance |
| Primary | Health related quality of life | Assessed at follow-up (at least 12 months after programme completion). | We will estimate health related quality of life using the short form survey questionnaire (SF36). |
| Secondary | Change in fat mass | Assessed at follow-up (at least 12 months after programme completion). | Change in fat mass measured by bioimpedance from programme completion to follow up visit. |
| Secondary | Waist circumference | Assessed at follow-up (at least 12 months after programme completion). | Waist circumference will be measured between lowest palpable rib and top of the hip. |
| Secondary | Lower body strength | Assessed at follow-up (at least 12 months after programme completion). | We will measure lower body strength with a 30-Seconds SST(19). The test will be performed by those of the patients who was tested at 21 months. |
| Secondary | Use of weight-loss medication | Assessed at follow-up (at least 12 months after programme completion). | We will calculate the percent of patients who continued weight-loss medication after cessation of the programme and evaluate the dosages they use. |
| Secondary | Changes in blood-pressure | Assessed at follow-up (at least 12 months after programme completion). | We will measure changes in blood-pressure from 21 months to follow-up. |
| Secondary | Changes in Hba1c | Assessed at follow-up (at least 12 months after programme completion). | We will measure changes in HbA1c from 21 months to follow-up and combine this with data on medication requirements. |
| Secondary | Changes in lipid levels | Assessed at baseline (programme-completion) and follow-up (at least 12 months). | We will measure changes in total cholesterol, HDL, LDL and triglycer-ides from 21 months to follow-up and combine this with data on medication requirements |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07900178/registered